계명대학교 의학도서관 Repository

Multicenter Prospective Observational Study of the Comparative Efficacy and Safety of Vancomycin versus Teicoplanin in Pateints with Health Care-Associated Methicillin-Resistant Staphylococcus aureus Bacteremia

Metadata Downloads
Author(s)
Young Kyung YoonDae Won ParkJang Wook SohnHyo Youl KimYeon-Sook KimChang-Seop LeeMi Suk LeeSeong-Yeol RyuHee-Chang JangYoung Ju ChoiCheol-In KangHee Jung ChoiSeung Soon LeeShin Woo KimSang Il KimEu Suk KimJeong Yeon KimKyung Sook YangKyong Ran PeckMin Ja Kim
Keimyung Author(s)
Ryu, Seong Yeol
Department
Dept. of Internal Medicine (내과학)
Journal Title
Antimicrobial Agents and Chemotherapy
Issued Date
2014
Volume
58
Issue
1
Abstract
The purpose of this study was to compare the clinical efficacy and safety of vancomycin to those of teicoplanin for the treatment of adult patients with health care-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) bacteremia. A multicenter observational study was prospectively conducted in 15 teaching hospitals in Korea between February 2010 and July 2011. Adult patients (≥18 years old) with HA-MRSA bacteremia who were initially treated with vancomycin (VAN) (n = 134) or teicoplanin (TEC) (n = 56) were enrolled. Clinical and microbiological responses and drug-related adverse events were compared between the two treatment groups using univariate and multivariate logistic regression analyses. The vancomycin and teicoplanin MICs were determined by Etest. The MRSA-related mortality, duration of fever, and duration of MRSA bacteremia in the treatment groups were not significantly different. There was no significant difference in the occurrence of drug-related adverse events. Among the 190 MRSA isolates, the VAN MICs ranged from 0.5 to 2 μg/ml (MIC50 and MIC90, 1.5 μg/ml), and the TEC MIC ranged from 0.5 to 8 μg/ml (MIC50, 3 μg/ml; MIC90, 6 μg/ml). In multivariate analyses, the antibiotic type (vancomycin or teicoplanin) was not associated with treatment outcomes. This study indicates that teicoplanin is an effective and safe alternative to vancomycin for the treatment of HA-MRSA bacteremia.
Keimyung Author(s)(Kor)
류성열
Publisher
School of Medicine
Citation
Young Kyung Yoon et al. (2014). Multicenter Prospective Observational Study of the Comparative Efficacy and Safety of Vancomycin versus Teicoplanin in Pateints with Health Care-Associated Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 58(1), 317–324. doi: 10.1128/AAC.00520-13
Type
Article
ISSN
0066-4804
Source
http://aac.asm.org/content/58/1/317
DOI
10.1128/AAC.00520-13
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35064
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.